The costs of future polio risk management policies

Risk Analysis

Volumn 26, Issue 6, 2006, Pages 1507-1531

  Tebbens, Radboud J Duintjer ^a,b   Sangrujee, Nalinee ^c   Thompson, Kimberly M ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c Palladium Group   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Decision analysis; Economic evaluation; Financial risk; Polio eradication

Indexed keywords

DECISION THEORY; DISEASES; ECONOMIC AND SOCIAL EFFECTS; IMMUNIZATION; PUBLIC POLICY; STRATEGIC PLANNING; VACCINES;

ECONOMIC EVALUATION; FINANCIAL RISK; POLIO ERADICATION;

RISK MANAGEMENT;

INACTIVATED VIRUS VACCINE; ORAL POLIOMYELITIS VACCINE;

COST; DECISION MAKING; EXPENDITURE; HEALTH POLICY; IMMUNIZATION; POLIOMYELITIS; VACCINATION; VACCINE;

COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DRUG COST; EPIDEMIC; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; LOWEST INCOME GROUP; POLIOMYELITIS; REVIEW; RISK MANAGEMENT; SENSITIVITY ANALYSIS; VACCINATION;

COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; MODELS, ECONOMIC; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; PUBLIC HEALTH; REPRODUCIBILITY OF RESULTS; RISK; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; WORLD HEALTH;

POLIOVIRUS;

EID: 33845674253     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2006.00842.x     Document Type: Review

References (89)

1. World Health Organization. (2004). Global Polio Eradication Initiative: Progress 2003. Report No.: WHO/Polio/04.01. Geneva.
2. Hull, H. F., & Aylward, R. B. (1997). Ending polio immunization. Science, 277(5327), 780.
3. World Health Organization. (1998). Report of The Meeting on the Scientific Basis for Stopping Polio Immunization.; Report No.: WHO/EPI/GEN/98.12. Geneva: World Health Organization.
4. Wood, D. J., Sutter, R. W., & Dowdle, W. R. (2000). Stopping poliovirus vaccination after eradication: Issues and challenges. Bulletin of the World Health Organization, 78(3), 347-357.
5. Wood, D. J. (2001). The scientific basis for stopping polio immunisation - Issues and challenges. Developments in Biologicals, 105, 69-72.
6. Cochi, S. L., Sutter, R. W., & Aylward, R. B. (2001). Possible global strategies for stopping polio vaccination and how they could be harmonized. Developments in Biologicals, 105, 153-158.
7. Technical Consultative Group of the World Health Organization on the Global Eradication of Poliomyelitis. (2002). Endgame issues for the global polio eradication initiative. Clinical Infectious Diseases, 34, 72-79.
8. Sangrujee, N., Duintjer Tebbens, R. J., Cáceres, V. M., & Thompson, K. M. (2003). Policy decision options during the first 5 years following certification of polio eradication. Medscape General Medicine, 5(4), 35.
9. Fine, P. E. M., Oblapenko, G., & Sutter, R. W. (2004). Polio control after certification: Major issues outstanding. Bulletin of the World Health Organization, 82(1), 47-52.
10. World Health Organization. (2004). Global Polio Eradication Initiative: Strategic Plan 2004-2008. Geneva.
11. World Health Organization. (2004). Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21-22 September 2004. Weekly Epidemiological Record, 79(45), 401-408.
12. Musgrove, P. (1988). Is polio eradication in the Americas economically justified? Bulletin of the Pan American Health Organization, 22(1), 1-16.
13. Bart, K., Foulds, J., & Patriarca, P. (1996). Global eradication of poliomyelitis: Benefit-cost analysis. Bulletin of the World Health Organization, 74, 35-45.
14. Kahn, M. M., & Ehreth J. (2003). Costs and benefits of polio eradication: A long-run global perspective. Vaccine, 21, 702-705.
15. Aylward, R. B., Acharya, A., England, S., Agocs, M., & Linkins, J. (2003). Global health goals: Lessons from the worldwide effort to eradicate poliomyelitis. Lancet, 362(9387), 909-914.
16. Sangrujee, N., Cáceres, V. M., & Cochi, S. L. (2004). Cost analysis of post-polio certification immunization policies. Bulletin of the World Health Organization, 82(1), 9-15.
17. Liu, X., Levin, A., Makinen, M., & Day, J. (February). OPV vs. IPV: Past and Future Choice of Vaccine in the Global Polio Eradication Program. Bethesda, MD: Partners for Health Reformplus Project, Abt Associates Inc.
18. Acharya, A., Diaz-Ortega, J. L., Tambini, G., de Quadros, C., & Arita, I. (2002). Cost-effectiveness of measles elimination in Latin America and the Caribbean: A prospective analysis. Vaccine, 20(27-28), 3332-3341.
19. Aggarwal, U., & Tezier, J. G. (2003). Personal communication: SIA comparison: Unit operations cost (2 rounds) for SIAs in Nepal and Myanmar. South East Asia Regional EPI Office, WHO.
20. Asian Development Bank. (2001). Immunization Financing in Developing Countries and the International Vaccine Market: Trends and Issues. Manila.
21. Aylward, R. B. (2004). Personal communication. Geneva: World Health Organization, Polio Eradication Initiative.
22. Belgisch Centrum voor Farmacotherapeutische Informatie. (2004). Vaccin tegen tetanus, difterie, kinkhoest en Hibinfecties: Available at http://www.bcfi.be, accessed June, 16 2004.
23. Cáceres, V. M., & Sutter, R. W. (2001). Sabin monovalent oral polio vaccines: Review of past experiences and their potential use after polio eradication. Clinical Infectious Diseases, 33(4), 531-541.
24. Centers for Disease Control and Prevention. (2004). CDC Vaccine Price List. National Immunization Program, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services: Available at http://www.cdc.gov/ nip/vfc/cdc vac_price_list.htm, accessed June, 4 2004.
25. Centers for Disease Control and Prevention. (2004). National laboratory inventory for global poliovirus containment - United States, November 2003. Morbidity and Mortality Weekly Report, 53(21), 457-459.
26. Centers for Disease Control and Prevention. (1996). Update: Mass vaccination with oral poliovirus vaccine - Asia and Europe, 1996. Morbidity and Mortality Weekly Report, 45(42), 911-914.
27. Costa, A. (2002). Ensuring Vaccine Supply for Accelerated Disease Control Initiatives [Presented at the meeting of the strategic advisory group of experts]. World Health Organization: Available at http://www.who.int/ vaccinesaccess/supply/Ensuring_Vaccine_supply%20.ppt, accessed March 11, 2005
28. Creese, A. L. (1984). Cost effectiveness of alternative strategies for poliomyelitis immunization in Brazil. Rev Infect Dis, 6(Suppl 2), S404-S407.
29. de Gourville, E. M., Sangrujee, N., Duintjer Tebbens, R. J., & Thompson, K. M. (2006). Global surveillance and the value of information: The case of the global polio laboratory network, Risk Analysis, 26(6), 1557-1569.
30. Dowdle, W. R., de Gourville, E., Kew, O. M., Pallansch, M. A., & Wood, D. J. (2003). Polio eradication: The OPV paradox. Reviews in Medical Virology, 13(5), 277-291.
31. Duintjer Tebbens, R. J., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Jafari, H., Cochi, S. L., et al. (2006). Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 26(6), 1471-1505.
32. Duintjer Tebbens, R. J., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Sutter, R. W., & Thompson, K. M. (2005). A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 162(4), 358-372.
33. Fine, P. E. M., Sutter, R. W., & Orenstein, W. A. (2001). Stopping a polio outbreak in the post-eradication era. Developments in Biologicals, 105, 129-147.
34. Global Alliance for Vaccines and Immunization. (2005). Investment Case for the Polio Stockpile. Available at http://www.vaccinealliance.org/resources/ 16brd 07.Polio_Stockpile_investment_case.pdf, accessed January 7 2006.
35. Global Polio Eradication Initiative. (2005). Monovalent Oral Polio Vaccines Fact Sheet. Available at http://www.polioeradication.org/content/ meetings/Media-Materials_12OctMediaEvent/mOPVFactSheetfinal.2005.pdf, accessed January 7 2006.
36. Griffiths, U. (2003). Personal communication: Polio vaccination costs. Geneva: Department of Vaccines & Biologicals, WHO.
37. Hall, S. (2003). Personal communication: IPV summary report (presented at the 8th meeting of the technical consultative group on the global eradication of poliomyelitis). Copenhagen: UNICEF
38. Hull, B. P., & Dowdle, W. R. (1997). Poliovirus surveillance: Building the global polio laboratory network. Journal of Infectious Diseases 175(Suppl 1), S113-S116.
39. Kew, O. M., Wright, P. F., Agol, V. I., Delpeyroux, F., Shimizu, H., Nathanson, N., & Pollansch, M. A. (2004). Circulating vaccine-derived polioviruses: Current state of knowledge. Bulletin of the World Health Organization, 82(1), 16-23.
40. Levin, A., Sujata, T., Afsar, A., Tanzi, V., Dougherty, L., & Kaddar, M. (2000). The Cost-Effectiveness of Mixes of Operational Aproaches to Polio Eradication: Findings of two Case Studies. Report No.: Special Initiatives Report No. 32 Bethesda, MD: Partnerships for Health Reform Project, Abt Associates Inc.
41. Linkins, J. (2001). Personal communication: Details of planned costs, 2002-2005 (comparison of scenarios), WHO. Geneva: World Health Organization.
42. Linkins, J. (2003). Personal communication: HQ estimated resource requirements for polio eradication activities, WHO african region. Geneva: World Health Organization.
43. Linkins, J. (2002). Personal communication: WHO financials. Geneva: World Health Organization.
44. Linkins, R. W., Mansour, E., Wassif, O., Hassan, M. H., & Patriarca, P. A. (1995). Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt. Bull World Health Organ, 73(5), 589-595.
45. MacLennan, C., Dunn, G., Huissoon, A. P., Kumararatne, D. S., Martin, J., O'Leary, P., Thompson, R. A., Osman, H., Wood, P., Minor, P., Wood, D. J., & Pillay, D. (2004). Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet, 363(9420), 1509-1513.
46. Miller, M. A., Sutter, R. W., Strebel, P. M., & Hadler, S. C. (1996). Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. Journal of the American Medical Association, 276(12), 967-971.
47. Ministry of Health, Brazil. (1984). Memória sobre estimativa de custos dos casos de poliomielite no Brasil em 1982. Brasilia.
48. Mukherjee, A., Ahluwalia, T. P., Gaur, L. N., Mittal, R., Kambo, I., Saxena, N. C., & Singh, P. (2004). Assessment of vaccine wastage during a pulse polio immunization programme in India. J Health Popul Nutr, 22(1), 13-18.
49. Nguyen, V. H. (2005). Personal communication: Unpublished projections. Lyon, France: Sanofi Pasteur.
50. Pan American Health Organization. (2004). Introduction of Haemophilus Influenzae Type B Vaccine in the Americas. Available at http://www.paho.org/ English/HVP/HVI/hvp_hib_text.htm, accessed August, 20 2004.
51. Patriarca, P. A., Sutter, R. W., & Oostvogel, P. M. (1997). Outbreaks of paralytic poliomyelitis, 1976-1995. Journal of Infectious Diseases, 175(Suppl 1), S165-S172.
52. Patriarca, P. A., Wright, P. F., & John, T. J. (1991). Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Reviews of Infectious Diseases, 13, 926-939.
53. Prevots, D. R., Ciofi degli Atti, M. L., Sallabanda, A., Diamanti, E., Aylward, R. B., Kakariqqi, E., et al.. (1998). Outbreak of paralytic poliomyelitis in Albania, 1996: High attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clinical Infectious Diseases, 26(2), 419-425.
54. Setia, S., Mainzer, H., Washington, M. L., Coil, G., Snyder, R., & Weniger, B. G. (2002). Frequency and causes of vaccine wastage. Vaccine, 20(7-8), 1148-1156.
55. Smith, J., Leke, R., Adams, A., & Tangermann, R. H. (2004). Certification of polio eradication: Process and lessons learned. Bulletin of the World Health Organization, 82(1), 24-29.
56. Tucker, A. W., Isaacs, D., & Burgess, M. (2001). Costeffectiveness of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Australian and New Zealand Journal of Public Health, 25(5), 411-416.
57. UNICEF. (2003). The State of the World's Children 2003. Available at http://www.unicef.org/sowc03/tables/index.html, accessed July, 31 2003.
58. UNICEF. (2003) 2003 Vaccine Projection. Supply Division. Available at http://www.unicef.org/supply/2003_Vaccine_Projection.pdf, accessed June, 15 2004.
59. World Bank. (2002). World Bank List of Economies (July 2002). Available at http://www.worldbank.org/data/databytopic/CLASS.XLS, accessed December 2002.
60. World Bank. (2004). World Development Indicators 2004: Table 1.1. Size of the Economy. World Bank. Available at http://www.worldbank.org/data/wdi2004/ pdfs/table11.pdf, accessed July, 21 2004.
61. World Health Organization. (2001). Global Polio Eradication Initiative: Estimated External Financial Resource Requirements for 2002-2005. As of 1, September 2002. Report No.: WHO/Polio/01.05 Geneva: WHO and UNICEF.
62. World Health Organization. (2001August). Guidelines on the Detection, Notification and Response to a Suspected Outbreak of Poliomyelitis. Geneva: Global Polio Eradication Initiative, WHO.
63. World Health Organization. (2002). Report of the Seventh Meeting of the Global Technical Consultative Group for Poliomyelitis eradication. Geneva: Department of Vaccines and Biologicals, World Health Organization.
64. World Health Organization. (2002). WHO Vaccine-Preventable Diseases: Monitoring system. 2002 Global Summary. Report No.: WHO/V&B/02.20 Geneva: Immunization Vaccines and Biologicals, WHO.
65. World Health Organization. (2003). Global Polio Eradication Initiative: Estimated External Financial Resource Requirements for 2004-2008. As of December 2003. Geneva: WHO and UNICEF.
66. World Health Organization. (2003). Guidelines for Environmental Surveillance of Poliovirus Circulation. Geneva: Department of Vaccines & Biologicals, WHO.
67. World Health Organization. (2003). Monitoring Vaccine Wastage at the Country Level: Guidelines for Programma Managers. Geneva: Report No.: WHO/V&B/03.18. Geneva: World Health Organization.
68. World Health Organization. (2004). Unpublished projections: Department of Immunization Vaccines and Biologicals.
69. World Health Organization. (2004). WHO Global Action Plan for Laboratory Containment of Wild Polioviruses, 2nd ed. Report No.: WHO/V&B/03.11. Geneva: World Health Organization.
70. World Health Organization. (2004). WHO Vaccine-Preventable Diseases: Monitoring System. 2004 Global Summary. Report No.: WHO/IVB/2004. Geneva: Immunization Vaccines and Biologicals, WHO.
71. World Health Organization. (2004). Wild poliovirus importations in west and central Africa, January 2003-March 2004. Weekly Epidemiological Record, 22(79), 206-210.
72. World Health Organization. (2005). Immunization Financing. Immunization, Vaccines and Biologicals. Available at http://www.who.int/immunization financing/en/, accessed March 8 2005.
73. Zhang, J., Yu, J.-J, Zhang, R.-Z, Zhang, X.-L, Zhou, J., Wing, J. S., Schnur, A., & Wang, K.-A. (1998). Costs of polio immunization days in China: Implications for mass immunization campaign strategies. International Journal of Health Planning and Management, 13, 5-25.
74. Zuber, P. L., Yameogo, K. R., Yameogo, A., & Otten, M. W., Jr.. (2003). Use of administrative data to estimate mass vaccination campaign coverage, Burkina Faso, 1999. Journal of Infectious Diseases, 187(Suppl 1), S86-S90.
75. Kew, O. M., Sutter, R. W., de Gourville, E., Dowdle, W. R., & Pallansch, M. A. (2005). Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology, 59, 587-635.
76. Sutter, R. W., Cáceres, V. M., & Más Lago, P. (2004). The role of routine immunization in the post-certification era. Bulletin of the World Health Organization, 82(1), 31-38.
77. Gold, M. R., Siegel, J. E., Russel, L. B., & Weinstein, M. C. (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.
78. Aylward, R. B., & Cochi, S. L. (2004). Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bulletin of the World Health Organization, 82(1), 40-46.
79. World Health Organization. (2005). Final Report of the WHO Informal Consultation on Identification and Management of Vaccine-Derived Polioviruses. Geneva, in press.
80. Bureau of Labor Statistics, U.S. Department of Labor. (2002). Consumer Price Index. Available at ftp://ftp.bls.gov/pub/special.requests/cpi/cpiai.txt, accessed February 2002.
81. UN Population Division. (2003). World Population Prospects Population Database: The 2002 Revision Population Database. Available at http://esa.un.org/unpp/index.asp?panel=2, accessed July 31 2003.
82. Sutter, R. W. (2006). Personal communication. Geneva, Switzerland.
83. DuintjerTebbens, R. J., Thompson, K. M., Huninck, M., Mazzuchi, T. M., Lewandowski, D., Kurowicka, D., et al. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs, (in preparation).
84. Lewandowski, D., Duintjer Tebbens, R. J., & Cooke, R. M. (2005). Regression analysis and efficient estimation of correlation ratio, (in preparation).
85. Mascarenas, A., Salinas, J., Tasset-Tisseau, A., Mascarenas, C., & Khan, M. M.. Polio immunization policy in Mexico: Economic assessment of current practice and future alternatives. Public Health, 119(6), 542-549.
86. Shlyakter, A. (1995). An improved framework for uncertainty analysis: Accounting for unsuspected errors. Risk Analysis, 14(4), 441-447.
87. Yang, C., Naguib, T., Yang, S., Nasr, E., Jorba, J., Ahmed, N., et al. (2003). Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. Journal of Virology, 77(15), 8366-8377.
88. Sing, M., & Kaye, W. M. (1996). An overview of the market and regulatory context. In M. V. Pauly, C. A. Robinson, S. J. Sepe, M. Sing, & M. K. Willian (Eds.), Supplying Vaccines: An Economic Analysis of Critical Issues, 1st ed. (pp. 45-99). Amsterdam: IOS Press.
89. World Health Organization Regional Office for Africa, Centers for Disease Control and Prevention. (2001). Technical Guidelines for Integrated Disease Surveillance and Response in the African Region. Atlanta: Public Health Service, Centers for Disease Control and Prevention, Division of International Health, National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases.